ProCE Banner Activity

Frontline Treatment Considerations and Strategies for Patients With Newly Diagnosed DLBCL

Slideset Download
Download these slides from a live symposium to gain more insight into the frontline management of DLBCL.

Released: June 05, 2022

Expiration: June 04, 2023

No longer available for credit.

Share

Faculty

Grzegorz Nowakowski

Grzegorz Nowakowski, MD

Professor of Medicine and Oncology
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Genmab US

Incyte Corporation

Lilly

Faculty Disclosure

Primary Author

Grzegorz Nowakowski, MD

Professor of Medicine and Oncology
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Grzegorz S. Nowakowski, MD, has disclosed that he has received consulting fees from AbbVie, ADC Therapeutics, Bantam Pharmaceutical LLC, Blueprint Medicines, Bristol-Myers Squibb, Celgene Corporation, Curis, Debiopharm, F Hoffmann-La Roche Limited, Fate Therapeutics, Genentech, Incyte, Karyopharm Therapeutics, Kite Pharma, Kymera Therapeutics, MEI Pharma, MorphoSys AG, Ryvu Therapeutics, Seagen, Selvita Inc, TG Therapeutics, and Zai Lab Limited.